Ethyl 5-bromo-2,3-dihydro-1-benzofuran-2-carboxylate | 194163-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: Ethyl 5-bromo-2,3-dihydro-1-benzofuran-2-carboxylate
• CAS: 194163-36-5
• 化学式: C₁₁H₁₁BrO₃
• 分子量: 271.111
• InChiKey: FRWJLWVJGAUGGM-UHFFFAOYSA-N

物化性质

• 沸点：
  328.5±42.0 °C(Predicted)
• 密度：
  1.507±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Ethyl 5-bromo-2,3-dihydro-1-benzofuran-2-carboxylate 在 吡啶 、 4-二甲氨基吡啶 、 lithium hydroxide 、 copper(l) iodide 、 TEA 、 硫化氢 、 ammonium acetate 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 碘甲烷 作用下， 生成 Tert-butyl 7-[(5-carbamimidoyl-2,3-dihydro-1-benzofuran-2-carbonyl)amino]heptanoate
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k
• 作为产物：
  描述：

  [4-溴-2-(氯甲基)苯氧基]乙酸乙酯 在 sodium hydride 作用下， 生成 Ethyl 5-bromo-2,3-dihydro-1-benzofuran-2-carboxylate
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k

文献信息

• Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
  申请人：——

  公开号：US20030195352A1

  公开（公告）日：2003-10-16

  This invention relates to novel benzofuran and dihydrobenzofuran compounds, pharmaceutical compositions containing such compounds, and methods of treating beta-3 adrenoreceptor-mediated conditions with such compositions.

  这项发明涉及新型苯并呋喃和二氢苯并呋喃化合物，含有这些化合物的药物组合物，以及使用这些组合物治疗β-3肾上腺素受体介导的疾病的方法。
• BENZOFURAN AND DIHYDROBENZOFURAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS
  申请人：Bayer Pharmaceuticals Corporation

  公开号：EP1430043A1

  公开（公告）日：2004-06-23
• US6780859B2
  申请人：——

  公开号：US6780859B2

  公开（公告）日：2004-08-24
• [EN] BENZOFURAN AND DIHYDROBENZOFURAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS<br/>[FR] DERIVES DE BENZOFURANE ET DE DIHYDROBENZOFURANE UTILES COMME AGONISTES DU BETA-3 ADRENORECEPTEUR
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2003024948A1

  公开（公告）日：2003-03-27

  This invention relates to novel benzofuran and dihydrobenzofuran compounds, pharmaceutical compositions containing such compounds, and methods of treating beta-3 adrenoreceptor-mediated conditions with such compositions.
• Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists
  作者：Daniel J. Sall、Ann E. Arfsten、Jolie A. Bastian、Michael L. Denney、Cathy S. Harms、Jefferson R. McCowan、John M. Morin,、Jack W. Rose、Robert M. Scarborough、Mark S. Smyth、Suzane L. Um、Barbara G. Utterback、Robert T. Vasileff、James H. Wikel、Virginia L. Wyss、Joseph A. Jakubowski

  DOI：10.1021/jm970020k

  日期：1997.8.1

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.